Skip to main content

Table 2 Incidence of proliferative and apoptotic CTCs in CTC-positive DC and metastatic patients and their percentages among the total CTCs detected

From: Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy

 

CTC phenotype (n%)

Patient groups

I

II

III

IV

 

Dormant only a

Proliferative b

Apoptotic c

All phenotypes e

Dormancy candidates (n = 40)

25 (62.5)

7 (17.5)

4 (10)

4 (10)

Metastatic patients (n = 15)

8 (53.4)

7 (46.6)*

0 (0)

0 (0)

 

CTC phenotype (n %)

 

Dormant a

     Nondormant d

Number of CTCs

 

Proliferative b

Apoptotic c

Dormancy candidates (n = 244)

201 (82.4)

14 (5.7)

29 (11.9)

Metastatic patients (n = 142)

84 (59.1)**

58 (40.9)**

0 (0)

  1. Patients with aKi67(-)/M30(-) CTCs, bKi67(+)/M30(-) CTCs, cKi67(-)/M30(+) CTCs, dKi67(+)/M30(-) or Ki67(-)/M30(+) CTCs and epatients harboring all phenotypes. *P = 0.0394, **P <0.0001, compared to dormancy candidates. CTCs, circulating tumor cells; DC, dormancy candidates.